Gene test may predict who loses most weight on popular drugs
NCT ID NCT06069622
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study looks at whether a person's genetic makeup (specifically the CAV-1 gene) affects how well they respond to GLP-1 receptor agonist drugs (like Ozempic or Wegovy) for weight loss and heart health. Researchers will enroll 30 overweight or obese adults to measure changes in blood pressure and body weight after treatment. The goal is to understand why some people benefit more than others from these medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.